The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with Type 2 diabetes : A systematic review
Copyright © 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved..
This review comprehensively summarizes epidemiologic evidence of COVID-19 in patients with Type 2 diabetes, explores pathophysiological mechanisms, and integrates recommendations and guidelines for patient management. We found that diabetes was a risk factor for diagnosed infection and poor prognosis of COVID-19. Patients with diabetes may be more susceptible to adverse outcomes associated with SARS-CoV-2 infection due to impaired immune function and possible upregulation of enzymes that mediate viral invasion. The chronic inflammation caused by diabetes, coupled with the acute inflammatory reaction caused by SARS-CoV-2, results in a propensity for inflammatory storm. Patients with diabetes should be aware of their increased risk for COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Primary care diabetes - 15(2021), 6 vom: 29. Dez., Seite 899-909 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yin, Yun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 06.12.2021 Date Revised 01.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pcd.2021.08.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331421615 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331421615 | ||
| 003 | DE-627 | ||
| 005 | 20231225213427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pcd.2021.08.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331421615 | ||
| 035 | |a (NLM)34600859 | ||
| 035 | |a (PII)S1751-9918(21)00169-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yin, Yun |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with Type 2 diabetes |b A systematic review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2021 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a This review comprehensively summarizes epidemiologic evidence of COVID-19 in patients with Type 2 diabetes, explores pathophysiological mechanisms, and integrates recommendations and guidelines for patient management. We found that diabetes was a risk factor for diagnosed infection and poor prognosis of COVID-19. Patients with diabetes may be more susceptible to adverse outcomes associated with SARS-CoV-2 infection due to impaired immune function and possible upregulation of enzymes that mediate viral invasion. The chronic inflammation caused by diabetes, coupled with the acute inflammatory reaction caused by SARS-CoV-2, results in a propensity for inflammatory storm. Patients with diabetes should be aware of their increased risk for COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Management | |
| 650 | 4 | |a Pathophysiological mechanism | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Rohli, Kristen E |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Pengyue |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Haonan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuenan |e verfasserin |4 aut | |
| 700 | 1 | |a Dou, Qingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Xiangyi |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Shujuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Peng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Primary care diabetes |d 2007 |g 15(2021), 6 vom: 29. Dez., Seite 899-909 |w (DE-627)NLM18094911X |x 1878-0210 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:6 |g day:29 |g month:12 |g pages:899-909 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pcd.2021.08.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 6 |b 29 |c 12 |h 899-909 | ||